1. SAT0249 Safety, pharmacokinetics, pharmacodynamics and inhibition of T-cell dependent antibody response (TDAR) with MEDI4920, a novel, engineered CD40 ligand (CD40L) antagonist: results of a first-time-in-human study. (15th June 2017) Authors: Albulescu, MG; Gunsior, M; Li, J; Bush, J; Godwood, A; Miday, R; Grant, E; Howe, D; Faggioni, R; Roskos, L Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 867 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗